These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 9853983)

  • 1. Elevated free fosphenytoin concentrations in uremic sera: uremic toxins hippuric acid and indoxyl sulfate do not account for the impaired protein binding of fosphenytoin.
    Dasgupta A; Havlik D
    Ther Drug Monit; 1998 Dec; 20(6):658-62. PubMed ID: 9853983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uremic sera contain inhibitors that block digitoxin-valproic acid interaction.
    Dasgupta A; Paul A; Wells A
    Am J Med Sci; 2001 Oct; 322(4):204-8. PubMed ID: 11678517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fast atom bombardment mass spectrometric determination of the molecular weight range of uremic compounds that displace phenytoin from protein binding: absence of midmolecular uremic toxins.
    Dasgupta A; Malik S
    Am J Nephrol; 1994; 14(3):162-8. PubMed ID: 7977474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia.
    Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G
    J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unexpected suppression of free phenytoin concentration by salicylate in uremic sera due to the presence of inhibitors: MALDI mass spectrometric determination of molecular weight range of inhibitors.
    Biddle DA; Wells A; Dasgupta A
    Life Sci; 2000; 66(2):143-51. PubMed ID: 10666010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid in vitro conversion of fosphenytoin into phenytoin in sera of patients with liver disease: role of alkaline phosphatase.
    Dasgupta A; Schlette E
    J Clin Lab Anal; 2001; 15(5):244-50. PubMed ID: 11574952
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phenytoin-oxacillin interactions in normal and uremic sera.
    Dasgupta A; Sperelakis A; Mason A; Dean R
    Pharmacotherapy; 1997; 17(2):375-8. PubMed ID: 9085332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin.
    Lai CM; Moore P; Quon CY
    Res Commun Mol Pathol Pharmacol; 1995 Apr; 88(1):51-62. PubMed ID: 7620838
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carbamazepine-salicylate interaction in normal and uremic sera: reduced interaction in uremic sera.
    Dasgupta A; Thompson WC
    Ther Drug Monit; 1995 Apr; 17(2):199-202. PubMed ID: 7624911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elevated free phenytoin and free valproic acid concentrations in sera of patients infected with human immunodeficiency virus.
    Dasgupta A; McLemore JL
    Ther Drug Monit; 1998 Feb; 20(1):63-7. PubMed ID: 9485557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased free phenytoin concentrations in predialysis serum compared to postdialysis serum in patients with uremia treated with hemodialysis. Role of uremic compounds.
    Dasgupta A; Abu-Alfa A
    Am J Clin Pathol; 1992 Jul; 98(1):19-25. PubMed ID: 1615921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucuronidation of prodrug reactive site: isolation and characterization of oxymethylglucuronide metabolite of fosphenytoin.
    Annesley TM; Kurzyniec S; Nordblom GD; Buchanan N; Pool W; Reily M; Talaat R; Roberts WL
    Clin Chem; 2001 May; 47(5):910-8. PubMed ID: 11325896
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploring binding characteristics and the related competition of different protein-bound uremic toxins.
    Deltombe O; de Loor H; Glorieux G; Dhondt A; Van Biesen W; Meijers B; Eloot S
    Biochimie; 2017 Aug; 139():20-26. PubMed ID: 28528271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid-ketoconazole interaction in normal, hypoalbuminemic, and uremic sera: lack of interaction in uremic serum caused by the presence of inhibitor.
    Dasgupta A; Luke M
    Ther Drug Monit; 1997 Jun; 19(3):281-5. PubMed ID: 9200768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays.
    Kugler AR; Annesley TM; Nordblom GD; Koup JR; Olson SC
    Clin Chem; 1998 Jul; 44(7):1474-80. PubMed ID: 9665426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temperature dependence of phenytoin-protein binding in serum: effects of uremia and hypoalbuminemia.
    Allison TB; Comstock TJ
    Ther Drug Monit; 1988; 10(4):376-81. PubMed ID: 3201522
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diminished protein binding capacity of uremic sera for valproate following hemodialysis: role of free fatty acids and uremic compounds.
    Dasgupta A; Jacques M; Malhotra D
    Am J Nephrol; 1996; 16(4):327-33. PubMed ID: 8739287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro displacement of phenytoin from protein binding by nonsteroidal antiinflammatory drugs tolmetin, ibuprofen, and naproxen in normal and uremic sera.
    Dasgupta A; Timmerman TG
    Ther Drug Monit; 1996 Feb; 18(1):97-9. PubMed ID: 8848829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Displacement by anionic drugs of endogenous ligands bound to albumin in uremic serum.
    Mabuchi H; Nakahashi H
    Ther Drug Monit; 1988; 10(3):261-4. PubMed ID: 3140432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Uricosuric agents in uremic sera. Identification of indoxyl sulfata and hippuric acid.
    Boumendil-Podevin EF; Podevin RA; Richet G
    J Clin Invest; 1975 Jun; 55(6):1142-52. PubMed ID: 1133164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.